BridgeMD
Tests treatment safety and results for Hemorrhoid
Official title Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids
ClinicalTrials.gov ID: NCT07128979
What this study is testing
What is Neoven 225 mg capsules?
Neoven 225 mg capsules is an investigational medicine, given as a twice-daily infusion into a vein, being studied as a potential treatment for hemorrhoid.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Hemorrhoidal disease is characterized by distal displacement and deterioration of structural integrity of vascular cushions in the anal canal, which physiologically help defecation and continence. Unlike advanced stage (stage IV) hemorrhoids, which require surgical intervention, various topical agents (gels, ointments, creams), oral venoactive drugs, homeopathic and phytotherapeutic products and nutritional supplements are widely used in stage II and III hemorrhoidal disease.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45
You may be able to join if
- Patients between the ages of 18-45 with complaints (symptomatic) consistent with hemorrhoidal disease
- Patients with Stage II and III hemorrhoids according to the Goligher Hemorrhoid Rating system using physical examination (digital rectal examination...
- Patients who have signed the Informed Consent Form
You likely can't join if
- Patients aged \ 45 years
- Stage I and IV hemorrhoids according to the Goligher Hemorrhoid Rating system
- Surgery for hemorrhoids at any time
- Injection treatment for multiple hemorrhoids in the last 3 years
- Perianal sepsis, inflammatory bowel disease, colorectal malignancy, or pre-existing sphincter injury within the last 3 years
- Immunodeficiency
See the full eligibility criteria
- Patients between the ages of 18-45 with complaints (symptomatic) consistent with hemorrhoidal disease
- Patients with Stage II and III hemorrhoids according to the Goligher Hemorrhoid Rating system using physical examination (digital rectal examination, anoscopy/rectoscopy performed within a maximum of four weeks before...
- Patients who have signed the Informed Consent Form
- Patients aged \ 45 years
- Stage I and IV hemorrhoids according to the Goligher Hemorrhoid Rating system
- Surgery for hemorrhoids at any time
- Injection treatment for multiple hemorrhoids in the last 3 years
- Perianal sepsis, inflammatory bowel disease, colorectal malignancy, or pre-existing sphincter injury within the last 3 years
- Immunodeficiency
- In addition to hemorrhoids, patients with anal fissures and perianal fistulas detected by simultaneous physical examination or anoscopy/rectoscopy
The study team makes the final eligibility decision.
Where it's taking place
- Istanbul, Turkey (Türkiye)
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Istanbul, Turkey (Türkiye). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.